Joshua A Bell1,2, Diana L Santos Ferreira3,4, Abigail Fraser3,4, Ana Luiza G Soares3,4, Laura D Howe3,4, Deborah A Lawlor3,4,5, David Carslake3,4, George Davey Smith3,4,5, Linda M O'Keeffe3,4,6. 1. MRC Integrative Epidemiology Unit at the University of Bristol, Oakfield House, Bristol, BS8 2BN, UK. j.bell@bristol.ac.uk. 2. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. j.bell@bristol.ac.uk. 3. MRC Integrative Epidemiology Unit at the University of Bristol, Oakfield House, Bristol, BS8 2BN, UK. 4. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. 5. Bristol NIHR Biomedical Research Centre, Bristol, UK. 6. School of Public Health, Western Gateway Building, University College Cork, Cork, Ireland.
Abstract
BACKGROUND: Males experience higher rates of coronary heart disease (CHD) than females, but the circulating traits underpinning this difference are poorly understood. We examined sex differences in systemic metabolites measured at four life stages, spanning childhood to middle adulthood. METHODS: Data were from the Avon Longitudinal Study of Parents and Children (7727 offspring, 49% male; and 6500 parents, 29% male). Proton nuclear magnetic resonance (1H-NMR) spectroscopy from a targeted metabolomics platform was performed on EDTA-plasma or serum samples to quantify 229 systemic metabolites (including lipoprotein-subclass-specific lipids, pre-glycaemic factors, and inflammatory glycoprotein acetyls). Metabolites were measured in the same offspring once in childhood (mean age 8 years), twice in adolescence (16 years and 18 years) and once in early adulthood (25 years), and in their parents once in middle adulthood (50 years). Linear regression models estimated differences in metabolites for males versus females on each occasion (serial cross-sectional associations). RESULTS: At 8 years, total lipids in very-low-density lipoproteins (VLDL) were lower in males; levels were higher in males at 16 years and higher still by 18 years and 50 years (among parents) for medium-or-larger subclasses. Larger sex differences at older ages were most pronounced for VLDL triglycerides-males had 0.19 standard deviations (SD) (95% CI = 0.12, 0.26) higher at 18 years, 0.50 SD (95% CI = 0.42, 0.57) higher at 25 years, and 0.62 SD (95% CI = 0.55, 0.68) higher at 50 years. Low-density lipoprotein (LDL) cholesterol, apolipoprotein-B, and glycoprotein acetyls were generally lower in males across ages. The direction and magnitude of effects were largely unchanged when adjusting for body mass index measured at the time of metabolite assessment on each occasion. CONCLUSIONS: Our results suggest that males begin to have higher VLDL triglyceride levels in adolescence, with larger sex differences at older ages. Sex differences in other CHD-relevant metabolites, including LDL cholesterol, show the opposite pattern with age, with higher levels among females. Such life course trends may inform causal analyses with clinical endpoints in specifying traits which underpin higher age-adjusted CHD rates commonly seen among males.
BACKGROUND: Males experience higher rates of coronary heart disease (CHD) than females, but the circulating traits underpinning this difference are poorly understood. We examined sex differences in systemic metabolites measured at four life stages, spanning childhood to middle adulthood. METHODS: Data were from the Avon Longitudinal Study of Parents and Children (7727 offspring, 49% male; and 6500 parents, 29% male). Proton nuclear magnetic resonance (1H-NMR) spectroscopy from a targeted metabolomics platform was performed on EDTA-plasma or serum samples to quantify 229 systemic metabolites (including lipoprotein-subclass-specific lipids, pre-glycaemic factors, and inflammatory glycoprotein acetyls). Metabolites were measured in the same offspring once in childhood (mean age 8 years), twice in adolescence (16 years and 18 years) and once in early adulthood (25 years), and in their parents once in middle adulthood (50 years). Linear regression models estimated differences in metabolites for males versus females on each occasion (serial cross-sectional associations). RESULTS: At 8 years, total lipids in very-low-density lipoproteins (VLDL) were lower in males; levels were higher in males at 16 years and higher still by 18 years and 50 years (among parents) for medium-or-larger subclasses. Larger sex differences at older ages were most pronounced for VLDL triglycerides-males had 0.19 standard deviations (SD) (95% CI = 0.12, 0.26) higher at 18 years, 0.50 SD (95% CI = 0.42, 0.57) higher at 25 years, and 0.62 SD (95% CI = 0.55, 0.68) higher at 50 years. Low-density lipoprotein (LDL) cholesterol, apolipoprotein-B, and glycoprotein acetyls were generally lower in males across ages. The direction and magnitude of effects were largely unchanged when adjusting for body mass index measured at the time of metabolite assessment on each occasion. CONCLUSIONS: Our results suggest that males begin to have higher VLDL triglyceride levels in adolescence, with larger sex differences at older ages. Sex differences in other CHD-relevant metabolites, including LDL cholesterol, show the opposite pattern with age, with higher levels among females. Such life course trends may inform causal analyses with clinical endpoints in specifying traits which underpin higher age-adjusted CHD rates commonly seen among males.
Authors: Gregory G Schwartz; Anders G Olsson; Markus Abt; Christie M Ballantyne; Philip J Barter; Jochen Brumm; Bernard R Chaitman; Ingar M Holme; David Kallend; Lawrence A Leiter; Eran Leitersdorf; John J V McMurray; Hardi Mundl; Stephen J Nicholls; Prediman K Shah; Jean-Claude Tardif; R Scott Wright Journal: N Engl J Med Date: 2012-11-05 Impact factor: 91.245
Authors: Brian A Ference; John J P Kastelein; Henry N Ginsberg; M John Chapman; Stephen J Nicholls; Kausik K Ray; Chris J Packard; Ulrich Laufs; Robert D Brook; Clare Oliver-Williams; Adam S Butterworth; John Danesh; George Davey Smith; Alberico L Catapano; Marc S Sabatine Journal: JAMA Date: 2017-09-12 Impact factor: 56.272
Authors: Qin Wang; Diana L Santos Ferreira; Scott M Nelson; Naveed Sattar; Mika Ala-Korpela; Debbie A Lawlor Journal: BMC Med Date: 2018-02-06 Impact factor: 8.775
Authors: Linda M O'Keeffe; Andrew J Simpkin; Kate Tilling; Emma L Anderson; Alun D Hughes; Debbie A Lawlor; Abigail Fraser; Laura D Howe Journal: Data Brief Date: 2019-01-19
Authors: Qin Wang; Peter Würtz; Kirsi Auro; Ville-Petteri Mäkinen; Antti J Kangas; Pasi Soininen; Mika Tiainen; Tuulia Tynkkynen; Jari Jokelainen; Kristiina Santalahti; Marko Salmi; Stefan Blankenberg; Tanja Zeller; Jorma Viikari; Mika Kähönen; Terho Lehtimäki; Veikko Salomaa; Markus Perola; Sirpa Jalkanen; Marjo-Riitta Järvelin; Olli T Raitakari; Johannes Kettunen; Debbie A Lawlor; Mika Ala-Korpela Journal: BMC Med Date: 2016-12-13 Impact factor: 8.775
Authors: Hagen M Gegner; Nils Mechtel; Elena Heidenreich; Angela Wirth; Fabiola Garcia Cortizo; Katrin Bennewitz; Thomas Fleming; Carolin Andresen; Marc Freichel; Aurelio A Teleman; Jens Kroll; Rüdiger Hell; Gernot Poschet Journal: Front Chem Date: 2022-04-25 Impact factor: 5.545
Authors: Linda M O'Keeffe; Joshua A Bell; Kate N O'Neill; Matthew A Lee; Mark Woodward; Sanne A E Peters; George Davey Smith; Patricia M Kearney Journal: PLoS Med Date: 2022-01-06 Impact factor: 11.613
Authors: Deniz Türkmen; Jane A H Masoli; Chia-Ling Kuo; Jack Bowden; David Melzer; Luke C Pilling Journal: Br J Clin Pharmacol Date: 2022-02-14 Impact factor: 3.716
Authors: Inge Verkouter; Raymond Noordam; Nellie Y Loh; Ko Willems van Dijk; Peter L Zock; Dennis O Mook-Kanamori; Saskia le Cessie; Frits R Rosendaal; Fredrik Karpe; Costantinos Christodoulides; Renée de Mutsert Journal: J Clin Endocrinol Metab Date: 2021-10-21 Impact factor: 5.958